Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 2
1952 4
1953 4
1954 3
1959 1
1960 5
1961 4
1962 3
1963 2
1964 1
1965 5
1966 2
1967 2
1968 1
1969 3
1970 7
1971 2
1972 5
1973 5
1974 1
1975 6
1976 15
1977 5
1978 11
1979 5
1980 8
1981 9
1982 9
1983 13
1984 13
1985 7
1986 19
1987 22
1988 20
1989 20
1990 28
1991 49
1992 25
1993 39
1994 45
1995 49
1996 62
1997 59
1998 50
1999 74
2000 77
2001 87
2002 70
2003 119
2004 132
2005 155
2006 169
2007 199
2008 261
2009 219
2010 282
2011 287
2012 292
2013 320
2014 315
2015 309
2016 336
2017 309
2018 292
2019 308
2020 340
2021 355
2022 250
Text availability
Article attribute
Article type
Publication date

Search Results

5,590 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: lee ks. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Clinical Trial.
The protein landscape of chronic lymphocytic leukemia.
Meier-Abt F, Lu J, Cannizzaro E, Pohly MF, Kummer S, Pfammatter S, Kunz L, Collins BC, Nadeu F, Lee KS, Xue P, Gwerder M, Roiss M, Hüllein J, Scheinost S, Dietrich S, Campo E, Huber W, Aebersold R, Zenz T. Meier-Abt F, et al. Among authors: lee ks. Blood. 2021 Dec 16;138(24):2514-2525. doi: 10.1182/blood.2020009741. Blood. 2021. PMID: 34189564
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Winer EP, et al. Among authors: lee ks. Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4. Lancet Oncol. 2021. PMID: 33676601 Clinical Trial.
Predictive Models of Neurodevelopmental Outcomes After Neonatal Hypoxic-Ischemic Encephalopathy.
Peeples ES, Rao R, Dizon MLV, Johnson YR, Joe P, Flibotte J, Hossain T, Smith D, Hamrick S, DiGeronimo R, Natarajan G, Lee KS, Yanowitz TD, Mietzsch U, Wu TW, Maitre NL, Pallotto EK, Speziale M, Mathur AM, Zaniletti I, Massaro A; Children’s Hospitals Neonatal Consortium Hypoxic-Ischemic Encephalopathy Focus Group. Peeples ES, et al. Among authors: lee ks. Pediatrics. 2021 Feb;147(2):e2020022962. doi: 10.1542/peds.2020-022962. Epub 2021 Jan 15. Pediatrics. 2021. PMID: 33452064 Clinical Trial.
5,590 results